Cytokine Signalling Forum

CME Courses




« Return to Overview

Cytokine Signalling Inhibitors: Update from EULAR 2020

Cytokine Signalling Inhibitors: Update from EULAR 2020
Developed by CESAS Medical, under the auspices of the University of Glasgow This activity is supported by unrestricted educational grants from AbbVie, Gilead/Galapagos, Pfizer and Lilly

Release date: 29 July 2020
Estimated time to complete activity: 1 hour
Compatible with all modern internet browsers and mobile devices

EDUCATIONAL OBJECTIVES
After completing this activity, the learner will:
  • Understand the mode of action of JAK inhibitors
  • Be up to date on the safety and efficacy of JAK Inhibitors in RA, JIA and PsA
  • Understand the clinical predictors and comparative effectiveness of JAK inhibitors in patients with RA

TARGET AUDIENCE
This activity is designed for qualified rheumatologists of all levels of seniority, and other healthcare professionals involved in treating patients with inflammatory disease.

PROGRAMME OVERVIEW
EULAR 2020 presented new scientific and clinical information on cytokine signalling science that will shape the rheumatology treatment landscape. Data presented included those relating to JAK inhibitors in clinical practice and in development across RA, JIA and PsA.

In this activity, Cytokine Signalling Inhibitors: Update from EULAR 2020, international experts review and discuss key abstracts and data from EULAR 2020 specifically relating to the mode of action, safety and efficacy, and comparative effectiveness of JAK inhibitors.

This course, Cytokine Signalling Inhibitors: Update from EULAR 2020, outlines recent developments in cytokine signalling science in RA, JIA and PsA, and discusses the importance of these new data for clinical practice. The learner’s understanding of the information presented will be assessed following each of the course modules.

INSTRUCTIONS FOR PARTICIPATION
Participants must 1) read the activity information; 2) study the educational activity; 3) successfully complete the post-module assessments with a score of 80% or better; 4) and complete the evaluation form. Upon completion of the full activity, your certificate will be made available to download and print.

DISCLOSURE OF CONFLICTS OF INTEREST
CESAS Medical requires faculty, presenters, planners, managers, writers, and any other individuals who are in a position to influence the content of this activity to disclose any real and/or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly reviewed and resolved according to CESAS Medical policy.

Module Presenter Video Questions
Introduction
Professor Rieke Alten image
Professor Rieke Alten

Head of Department of Internal Medicine, Rheumatology,
Schlosspark-Klinik, University Medicine Berlin, Germany

Dr Rieke Alten is head of the department of internal Medicine, Rheumatology, Clinical Immunology, Osteology at Schlosspark-Klinik at University Medicine Berlin, where she also serves as the director of the Rheumatology Research Centre. She is a member of the Global Alliance for Patient Access and OMERACT Steering Committee of the Flare in Rheumatoid Arthritis Group. Dr Alten has served as a board member on many occasions for; German Medical Association, the institute for approval of drugs for the German Ministry of Health, “Kaiser-Friedrich-Stiftung” for postgraduate education in Germany and board member of the German Society of Rheumatology.
Prof. Rieke Alten (Bio)
02:30
Module 1 - Basic Science
Professor Rieke Alten image
Professor Rieke Alten

Head of Department of Internal Medicine, Rheumatology,
Schlosspark-Klinik, University Medicine Berlin, Germany

Dr Rieke Alten is head of the department of internal Medicine, Rheumatology, Clinical Immunology, Osteology at Schlosspark-Klinik at University Medicine Berlin, where she also serves as the director of the Rheumatology Research Centre. She is a member of the Global Alliance for Patient Access and OMERACT Steering Committee of the Flare in Rheumatoid Arthritis Group. Dr Alten has served as a board member on many occasions for; German Medical Association, the institute for approval of drugs for the German Ministry of Health, “Kaiser-Friedrich-Stiftung” for postgraduate education in Germany and board member of the German Society of Rheumatology.
Prof. Rieke Alten (Bio)
Professor Thomas Dörner image
Professor Thomas Dörner

Professor and Principal Investigator ,
Charité University Hospitals Berlin, Germany

Professor Thomas Dörner is a Professor of Rheumatology at Charité University Hospitals, Berlin, and group leader at the German Research Centre of Rheumatology, Berlin (DRFZ).

He qualified in medicine in 1990 at Charité University Hospitals, Berlin, and received his board certification in internal medicine in 1995. He undertook a postdoctoral fellowship at the University of Texas, Southwestern Medical Centre at Dallas, where he researched delineating molecular aspects of the B-cell receptor gene usage in autoimmune diseases.

Professor Dörner has led various clinical trials of rheumatic diseases, including systemic lupus erythematosus, Sjögren’s syndrome, rheumatoid arthritis and seronegative spondyloarthropathies. His research interests focus on the characterisation of disturbances of humoral autoimmunity and abnormalities of B cell subsets in the blood versus tissue. He also explores innovative therapeutic approaches with particular focus on B-cell directed therapy as well as improving diagnostic tools in autoimmune diseases.

Professor Dörner has served as a member of Editorial Boards of leading journals in rheumatology and immunology, including Arthritis & Rheumatism, Arthritis Research & Therapy, Annals of the Rheumatic Diseases. He has received a number of awards including the Senior Scholar Award of the American College of Rheumatology, the H Schultze Award of the German League Against Rheumatism, Randy Fischer Prize for Excellence in flow cytometry and the Schoen Award of the German Society of Rheumatology.

Prof. Thomas Dörner (Bio)
05:37 3
Module 2 - Safety and Efficacy
Professor Rieke Alten image
Professor Rieke Alten

Head of Department of Internal Medicine, Rheumatology,
Schlosspark-Klinik, University Medicine Berlin, Germany

Dr Rieke Alten is head of the department of internal Medicine, Rheumatology, Clinical Immunology, Osteology at Schlosspark-Klinik at University Medicine Berlin, where she also serves as the director of the Rheumatology Research Centre. She is a member of the Global Alliance for Patient Access and OMERACT Steering Committee of the Flare in Rheumatoid Arthritis Group. Dr Alten has served as a board member on many occasions for; German Medical Association, the institute for approval of drugs for the German Ministry of Health, “Kaiser-Friedrich-Stiftung” for postgraduate education in Germany and board member of the German Society of Rheumatology.
Prof. Rieke Alten (Bio)
Professor Thomas Dörner image
Professor Thomas Dörner

Professor and Principal Investigator ,
Charité University Hospitals Berlin, Germany

Professor Thomas Dörner is a Professor of Rheumatology at Charité University Hospitals, Berlin, and group leader at the German Research Centre of Rheumatology, Berlin (DRFZ).

He qualified in medicine in 1990 at Charité University Hospitals, Berlin, and received his board certification in internal medicine in 1995. He undertook a postdoctoral fellowship at the University of Texas, Southwestern Medical Centre at Dallas, where he researched delineating molecular aspects of the B-cell receptor gene usage in autoimmune diseases.

Professor Dörner has led various clinical trials of rheumatic diseases, including systemic lupus erythematosus, Sjögren’s syndrome, rheumatoid arthritis and seronegative spondyloarthropathies. His research interests focus on the characterisation of disturbances of humoral autoimmunity and abnormalities of B cell subsets in the blood versus tissue. He also explores innovative therapeutic approaches with particular focus on B-cell directed therapy as well as improving diagnostic tools in autoimmune diseases.

Professor Dörner has served as a member of Editorial Boards of leading journals in rheumatology and immunology, including Arthritis & Rheumatism, Arthritis Research & Therapy, Annals of the Rheumatic Diseases. He has received a number of awards including the Senior Scholar Award of the American College of Rheumatology, the H Schultze Award of the German League Against Rheumatism, Randy Fischer Prize for Excellence in flow cytometry and the Schoen Award of the German Society of Rheumatology.

Prof. Thomas Dörner (Bio)
35:23 4
Module 3 - Predictors of Effectiveness and Comparative Effectiveness
Professor Rieke Alten image
Professor Rieke Alten

Head of Department of Internal Medicine, Rheumatology,
Schlosspark-Klinik, University Medicine Berlin, Germany

Dr Rieke Alten is head of the department of internal Medicine, Rheumatology, Clinical Immunology, Osteology at Schlosspark-Klinik at University Medicine Berlin, where she also serves as the director of the Rheumatology Research Centre. She is a member of the Global Alliance for Patient Access and OMERACT Steering Committee of the Flare in Rheumatoid Arthritis Group. Dr Alten has served as a board member on many occasions for; German Medical Association, the institute for approval of drugs for the German Ministry of Health, “Kaiser-Friedrich-Stiftung” for postgraduate education in Germany and board member of the German Society of Rheumatology.
Prof. Rieke Alten (Bio)
Professor Thomas Dörner image
Professor Thomas Dörner

Professor and Principal Investigator ,
Charité University Hospitals Berlin, Germany

Professor Thomas Dörner is a Professor of Rheumatology at Charité University Hospitals, Berlin, and group leader at the German Research Centre of Rheumatology, Berlin (DRFZ).

He qualified in medicine in 1990 at Charité University Hospitals, Berlin, and received his board certification in internal medicine in 1995. He undertook a postdoctoral fellowship at the University of Texas, Southwestern Medical Centre at Dallas, where he researched delineating molecular aspects of the B-cell receptor gene usage in autoimmune diseases.

Professor Dörner has led various clinical trials of rheumatic diseases, including systemic lupus erythematosus, Sjögren’s syndrome, rheumatoid arthritis and seronegative spondyloarthropathies. His research interests focus on the characterisation of disturbances of humoral autoimmunity and abnormalities of B cell subsets in the blood versus tissue. He also explores innovative therapeutic approaches with particular focus on B-cell directed therapy as well as improving diagnostic tools in autoimmune diseases.

Professor Dörner has served as a member of Editorial Boards of leading journals in rheumatology and immunology, including Arthritis & Rheumatism, Arthritis Research & Therapy, Annals of the Rheumatic Diseases. He has received a number of awards including the Senior Scholar Award of the American College of Rheumatology, the H Schultze Award of the German League Against Rheumatism, Randy Fischer Prize for Excellence in flow cytometry and the Schoen Award of the German Society of Rheumatology.

Prof. Thomas Dörner (Bio)
06:30 3
Close
Professor Rieke Alten image
Professor Rieke Alten

Head of Department of Internal Medicine, Rheumatology,
Schlosspark-Klinik, University Medicine Berlin, Germany

Dr Rieke Alten is head of the department of internal Medicine, Rheumatology, Clinical Immunology, Osteology at Schlosspark-Klinik at University Medicine Berlin, where she also serves as the director of the Rheumatology Research Centre. She is a member of the Global Alliance for Patient Access and OMERACT Steering Committee of the Flare in Rheumatoid Arthritis Group. Dr Alten has served as a board member on many occasions for; German Medical Association, the institute for approval of drugs for the German Ministry of Health, “Kaiser-Friedrich-Stiftung” for postgraduate education in Germany and board member of the German Society of Rheumatology.
Prof. Rieke Alten (Bio)
01:21
Evaluation 16

Date of preparation: 27 July 20